Daiichi Sankyo splits to offload old assets and focus on oncology ambition
Japanese pharma major Daiichi Sankyo (TYO: 4568) is offloading 41 of its products in Japan as it prioritizes the stated aim of becoming a ‘global pharma innovator with competitive advantage in oncology’.
The long-listed products, which had combined revenues in the last financial year of 9.16 billion yen ($82 million), will go to the wholesaler Alfresa Holdings Corporation (TYO: 2784).
Because of the large number of products being transferred in the transaction, Daiichi Sankyo has opted for a company split with Alfresa Pharma as the succeeding company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze